Resources
Press Releases
Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines
Zeteo’s patient-centric needle free nasal delivery systems are commercially scalable to facilitate rapid deployment of drugs and vaccines to global populations Pflugerville, TX – 04 May 2022 (send2press) – Zeteo Biomedical LLC announced today the availability of the...
Zeteo Biomedical To Present At SXSW Texas Global Health Security Innovation Demo Day Event
TEXGHS Global Health Security Event Features International Agenda of Companies and Speakers AUSTIN, TX – 15 March 2021 – Zeteo Biomedical will present its nasal vaccine packaging and delivery device technologies at the TEXGHS Global Health Security Demo Day scheduled...
Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device For Vaccines and Pharmaceuticals
Sublingual delivery is an emerging strategy for vaccines AUSTIN, TX – 10 March 2021 – Zeteo Biomedical a privately held, biomedical device company, announced today it has been awarded a United States Patent for its “Oral Delivery Device and Methods” (US Patent...
Zeteo Biomedical Introduces ZEOx1 AquilaMD™ Ophthalmic Drug Delivery System
Zeteo’s patient-centric ophthalmic delivery systems are designed for precise, self-administration of preservative free drugs and biopharmaceuticals AUSTIN, TX – 01 June 2020 -- (PR.com) – Zeteo Biomedical LLC announced today the availability of the ZEOx1 AquilaMD™...
Presentations
SXSW GHSIW Conference – March 2022
Beyond The Bicep: Technology Platforms For Global Scale Packaging, Rapid Deployment and Self Administration Of Nasal Vaccines and Biomedical Countermeasures Timothy Sullivan, Founder and CEO of Zeteo Biomedical presents technology and a future vision for protecting...
Beyond the Bicep
Technology Platforms For Global Scale Packaging, Rapid Deployment and Self Administration Of Nasal Vaccines and Biomedical Countermeasures
The COVID-19 Vaccine (It’s Not a Shot in the Dark)
Vaccines have been around for quite a while, so why has the COVID-19 vaccine been such a hot-button topic? Why has the method of action, parameters for storage, and transportation been something so widely discussed? It’s great that this information is being provided...
Partners
The Nanovaccine Institute is a consortium of 70 researchers at 20 universities, research institutes, national laboratories, and companies, coordinated by Iowa State University. Our research is a transdisciplinary merger of expertise in immunology, nanotechnology, materials science, microbiology, neuroscience, cancer biology, gerontology, clinical science, and social science. We are developing nanovaccines and nanotherapeutics for respiratory infections, neural disorders, tropical diseases, cancer, aging, and veterinary diseases.